The Brain AT2R-a Potential Target for Therapy in Alzheimer's Disease and Vascular Cognitive Impairment: a Comprehensive Review of Clinical and Experimental Therapeutics.

Molecular Neurobiology
Heba A Ahmed, Tauheed Ishrat

Abstract

Dementia is a potentially avertable tragedy, currently considered among the top 10 greatest global health challenges of the twenty-first century. Dementia not only robs individuals of their dignity and independence, it also has a ripple effect that starts with the inflicted individual's family and projects to the society as a whole. The constantly growing number of cases, along with the lack of effective treatments and socioeconomic impact, poses a serious threat to the sustainability of our health care system. Hence, there is a worldwide effort to identify new targets for the treatment of Alzheimer's disease (AD), the leading cause of dementia. Due to its multifactorial etiology and the recent clinical failure of several novel amyloid-β (Aβ) targeting therapies, a comprehensive "multitarget" approach may be most appropriate for managing this condition. Interestingly, renin angiotensin system (RAS) modulators were shown to positively impact all the factors involved in the pathophysiology of dementia including vascular dysfunction, Aβ accumulation, and associated cholinergic deficiency, in addition to tau hyperphosphorylation and insulin derangements. Furthermore, for many of these drugs, the preclinical evidence is also support...Continue Reading

References

Apr 10, 1992·Science·J A Hardy, G A Higgins
May 19, 2004·Archives of Neurology·Zoe ArvanitakisDavid A Bennett
Dec 20, 2005·Lancet Neurology·Geert Jan BiesselsPhilip Scheltens
Oct 30, 2007·The Journal of Clinical Investigation·Jun WangGiulio Maria Pasinetti
Aug 22, 2008·Biochemical and Biophysical Research Communications·Masaki MogiMasatsugu Horiuchi
Oct 29, 2009·Journal of the Renin-angiotensin-aldosterone System : JRAAS·U Muscha SteckelingsThomas Unger
Jan 12, 2010·Journal of Alzheimer's Disease : JAD·M Paul Murphy, Harry LeVine
Jan 29, 2010·The New England Journal of Medicine·Henry W Querfurth, Frank M LaFerla
Mar 23, 2010·Cell·Christopher K GlassFred H Gage
Apr 15, 2010·Molecular Neurodegeneration·Hans H DietrichDavid M Holtzman
Sep 16, 2010·Nature Reviews. Neurology·Catrina Sims-RobinsonEva L Feldman
May 21, 2011·The Journal of Pathology·Ying LiuCheng-Xin Gong
Jun 29, 2011·Journal of Alzheimer's Disease : JAD·Neil M DaviesRichard M Martin
Jul 23, 2011·Stroke; a Journal of Cerebral Circulation·Philip B GorelickUNKNOWN American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Counci
Sep 21, 2011·Geriatrics & Gerontology International·Kazumasa KumeToshihiko Iwamoto
Oct 6, 2011·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Fei JingMasatsugu Horiuchi
Jan 31, 2012·Nature Neuroscience·Iryna BenilovaBart De Strooper
Apr 24, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Michael L JohnsonRobert O Morgan
May 4, 2012·Cold Spring Harbor Perspectives in Medicine·Christian HaassSangram Sisodia

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic

Related Concepts

Related Feeds

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.